<DOC>
	<DOC>NCT03100942</DOC>
	<brief_summary>The primary objective of this study is to assess the efficacy of filgotinib, GS-9876, and tirabrutinib (formerly GS-4059) in adults with active Sjogren's Syndrome (SjS).</brief_summary>
	<brief_title>Safety and Efficacy Study of Filgotinib, GS-9876 and Tirabrutinib in Adults With Active Sjogren's Syndrome</brief_title>
	<detailed_description />
	<mesh_term>Syndrome</mesh_term>
	<mesh_term>Sjogren's Syndrome</mesh_term>
	<criteria>Key Diagnosed with SjS according to American European Consensus Group (AECG) classification Active SjS as defined by an ESSDAI â‰¥ 5 Seropositivity for antibodies to SjSassociated antigens A and B (antiSSA or antiSSB) Key Concurrent treatment with any biologic disease modifying antirheumatic drug (bDMARD) (prior bDMARD treatment allowed with appropriate washout as per study protocol) Note: Other protocol defined Inclusion/Exclusion criteria may apply.</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>75 Years</maximum_age>
	<verification_date>March 2017</verification_date>
</DOC>